question,expected_answer,DeepSeek-R1_answer,DeepSeek-R1_match
When should genetic testing for cancer predisposition genes beyond BRCA1/2 be considered?,"Testing should be offered if high penetrance genes (e.g., PALB2, TP53) could influence therapy, surgical decisions, or family risk assessment.","Genetic testing beyond BRCA1/2 should be considered when there is a personal or family history suggestive of hereditary cancer syndromes, such as:  
- Early-onset cancers (e.g., breast/colorectal <50 years).  
- Multiple primary cancers in one individual.  
- Clustering of cancers linked to specific genes (e.g., ovarian, pancreatic, prostate, or Lynch-related cancers).  
- Rare tumors (e.g., medullary thyroid cancer, pheochromocytoma).  
- Tumor features (e.g., triple-negative breast cancer <60, microsatellite instability).  
- Known familial mutation in non-BRCA genes (e.g., PALB2, ATM, Lynch genes).  
- Ethnicity with higher prevalence of certain mutations.  
Genetic counseling is essential to assess risk and select appropriate multigene panels.",NO
How should patients with variants of uncertain significance (VUS) be managed after genetic testing?,VUS should not alter management; patients should be followed up for reclassification and informed that reclassification is possible.,"Patients with a **VUS** should be managed based on personal/family history and established guidelines, **not** the VUS itself. Key steps:  
1. **Avoid altering clinical care** solely due to the VUS.  
2. **Re-evaluate periodically** as classifications may change with new evidence.  
3. **Counsel patients** to clarify uncertainty and address anxiety.  
4. **Rely on family/personal risk factors** to guide surveillance/prevention.  
5. **Collaborate with genetic specialists** for updates and tailored advice.",YES
What germline testing strategy is recommended for patients with recurrent breast cancer?,BRCA1/2 testing is recommended regardless of family history for patients who are candidates for PARP inhibitor therapy.,"For patients with recurrent breast cancer, comprehensive germline testing is recommended, including **BRCA1/2** and other high-risk genes (e.g., PALB2, TP53, ATM, CHEK2) via a multi-gene panel. Testing should be offered regardless of prior history if not previously performed, as results may guide targeted therapies (e.g., PARP inhibitors for BRCA1/2 mutations). Genetic counseling is essential** to interpret results and assess familial risk.",NO
What HER2 testing criteria should be used to determine eligibility for trastuzumab deruxtecan?,Patients with IHC 1+ or 2+/ISH not-amplified results are eligible; IHC 0 results are currently excluded.,"Eligibility for trastuzumab deruxtecan (T-DXd) depends on HER2 status determined by immunohistochemistry (IHC) and in situ hybridization (ISH):  
- **Breast cancer (metastatic):**  
  - **HER2-positive:** IHC 3+ or IHC 2+ with ISH-confirmed amplification (traditional HER2+).  
  - **HER2-low:** IHC 1+ or IHC 2+ without ISH amplification (no HER2 overexpression/gene amplification).  
- **Gastric/GEJ adenocarcinoma:** HER2-positive (IHC 3+ or IHC 2+ with ISH amplification).  
Testing must follow validated ASCO/CAP guidelines to ensure accuracy. Always refer to current regulatory approvals and clinical context.",NO
What are the best practices for distinguishing HER2 IHC 0 from 1+ results?,"Use standardized ASCO-CAP guidelines, high-power examination, second pathologist review, and careful attention to preanalytic conditions.","To distinguish HER2 IHC 0 from 1+ results, adhere to these best practices:  
1. **Follow ASCO/CAP Guidelines**:  
   - **0**: No staining or faint, incomplete membrane staining in ≤10% of tumor cells.  
   - **1+**: Faint/barely perceptible incomplete membrane staining in >10% of cells.  
2. **Assess Staining Characteristics**: Focus on membrane (not cytoplasmic) staining intensity and completeness (circumferential vs. partial).  
3. **Quantify Tumor Cells**: Ensure accurate calculation of stained cells (>10% for 1+).  
4. **Use Controls**: Include positive/negative controls to validate assay performance.  
5. **Ensure Proper Fixation**: Fix tissue in 10% neutral buffered formalin (6–72 hours) to avoid artifacts.  
6. **Train Pathologists**: Minimize interobserver variability via expert review or consensus for borderline cases.  
7. **Validate Assays**: Use standardized, approved IHC protocols and reagents.  

These steps enhance accuracy in distinguishing 0 (negative) from 1+ (negative/low expression) results.",YES
"What treatment is recommended for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on endocrine therapy and have received two prior lines of chemotherapy?","The use of sacituzumab govitecan (SG) is recommended based on evidence from the TROPiCS-02 trial, which demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to treatment of physician's choice.","The recommended treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on endocrine therapy and received two prior lines of chemotherapy is **Sacituzumab govitecan**, an antibody-drug conjugate approved in this setting. Additional options depend on molecular markers:  
- **PIK3CA mutation**: Alpelisib + fulvestrant.  
- **BRCA mutation**: PARP inhibitors (e.g., olaparib).  
- **Other options**: Everolimus + exemestane or further chemotherapy regimens (e.g., eribulin, capecitabine).  

Sacituzumab govitecan is prioritized based on recent guidelines for this specific scenario.",NO
"For HER2-low metastatic breast cancer (IHC 1+ or 2+, ISH-negative) previously treated with one chemotherapy, what therapy offers improved survival?","Trastuzumab deruxtecan is recommended, offering a median PFS of 9.9 months and median OS of 23.4 months, based on DESTINY-Breast04 trial findings.","Trastuzumab deruxtecan (T-DXd) significantly improves progression-free and overall survival in HER2-low (IHC 1+/2+ with negative ISH) metastatic breast cancer after prior chemotherapy, as demonstrated in the DESTINY-Breast04 trial. It is the standard-of-care in this setting.",YES
"In patients with hormone receptor-positive, HER2-negative metastatic breast cancer and ESR1 mutations detected in ctDNA, what is the preferred therapy after prior CDK4/6 inhibitor treatment?",Elacestrant is recommended as it showed improved PFS compared to standard endocrine therapy in the EMERALD trial.,"The preferred therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations detected in ctDNA after prior CDK4/6 inhibitor treatment is **elacestrant**, an oral selective estrogen receptor degrader (SERD). This recommendation is supported by the EMERALD trial, which demonstrated improved progression-free survival with elacestrant over standard endocrine therapy in this population. If elacestrant is unavailable, fulvestrant (a traditional SERD) may be considered.",YES
What considerations are necessary when prescribing trastuzumab deruxtecan for HER2-low metastatic breast cancer?,"Patients should be monitored for interstitial lung disease, which occurred in 12.1% of patients treated with trastuzumab deruxtecan in the DESTINY-Breast04 trial.","When prescribing trastuzumab deruxtecan (T-DXd) for HER2-low metastatic breast cancer, key considerations include:  
1. **HER2 Status Confirmation**: Ensure HER2-low expression (IHC 1+ or 2+/ISH-negative) via validated testing.  
2. **Prior Therapy**: Typically used after 1–2 prior chemotherapy lines in the metastatic setting.  
3. **Adverse Effect Monitoring**: Vigilant screening for interstitial lung disease (ILD)/pneumonitis (baseline and periodic imaging) and hematologic toxicities (e.g., neutropenia).  
4. **Dose Adjustments**: Adjust for organ dysfunction, adverse events (e.g., ILD), or comorbidities (e.g., pre-existing lung disease).  
5. **Contraindications**: Avoid in pregnancy; assess for drug interactions.  
6. **Patient Education**: Counsel on early symptoms of ILD (e.g., cough, dyspnea) and emphasize prompt reporting.  
7. **Cardiac and Performance Status**: Baseline assessment of cardiac function and fitness for treatment.  

Adherence to these factors optimizes safety and efficacy.",YES
"What are the therapy options for hormone receptor-positive, HER2-negative metastatic breast cancer with PIK3CA mutations?",Endocrine therapy combined with alpelisib,"Therapy options for hormone receptor-positive, HER2-negative metastatic breast cancer with **PIK3CA mutations** include:  
1. **First-line**: Endocrine therapy (e.g., aromatase inhibitors, fulvestrant) combined with **CDK4/6 inhibitors** (e.g., palbociclib, ribociclib).  
2. **Targeted therapy**: After progression on endocrine therapy, **alpelisib (PI3Kα inhibitor) + fulvestrant** is recommended for confirmed PIK3CA mutations.  
3. **Alternatives**: Everolimus (mTOR inhibitor) + exemestane or chemotherapy.  
4. **Clinical trials** for novel agents (e.g., AKT inhibitors).  

Testing for PIK3CA mutations (via tissue or liquid biopsy) is critical to guide targeted therapy selection.",YES
"How effective is elacestrant for ESR1 wild-type tumors in hormone receptor-positive, HER2-negative metastatic breast cancer?","Elacestrant is not significantly more effective than standard endocrine therapy for ESR1 wild-type tumors, as demonstrated in the EMERALD trial.","Elacestrant shows **limited effectiveness** in **ESR1 wild-type tumors** compared to ESR1-mutated tumors in hormone receptor-positive, HER2-negative metastatic breast cancer. In the EMERALD phase 3 trial, while elacestrant significantly improved progression-free survival (PFS) in patients with ESR1 mutations, the benefit in the ESR1 wild-type subgroup was **modest and not statistically significant**. Thus, its primary clinical utility is more pronounced in ESR1-mutated cases.",YES
"For HER2-negative metastatic breast cancer refractory to endocrine therapy, should single-agent chemotherapy or sacituzumab govitecan be offered?","Single-agent chemotherapy is preferred, starting with agents like capecitabine or eribulin","Sacituzumab govitecan is preferred over single-agent chemotherapy for HER2-negative metastatic breast cancer refractory to endocrine therapy **in patients who have received prior chemotherapy** (e.g., ≥2 lines), based on improved progression-free and overall survival in trials like TROPiCS-02. If no prior chemotherapy, single-agent chemotherapy remains the initial option.",NO
"In hormone receptor-positive, HER2-negative metastatic breast cancer, when should ctDNA testing be performed?","ctDNA testing is recommended at recurrence or progression on endocrine therapy, as ESR1 mutations often emerge under treatment pressure.","ctDNA testing in hormone receptor-positive, HER2-negative metastatic breast cancer is recommended **at disease progression** to detect resistance mutations (e.g., *ESR1*, *PIK3CA*) when tissue biopsy is unavailable or impractical. This helps guide targeted therapy selection (e.g., elacestrant for *ESR1* mutations, alpelisib for *PIK3CA*). It is not a first-line replacement for tissue biopsy but serves as a less invasive alternative in advanced settings.",YES
"What is the recommendation for premenopausal women with node-positive, ER-positive, HER2-negative breast cancer?",Oncotype DX should not be used to guide chemotherapy decisions for premenopausal women with node-positive disease.,"For premenopausal women with node-positive, ER-positive, HER2-negative breast cancer, the recommendation is **adjuvant endocrine therapy with ovarian function suppression (OFS)** combined with either an aromatase inhibitor (preferred) or tamoxifen, plus **adjuvant chemotherapy** based on tumor biology and risk assessment (e.g., high recurrence score). Treatment duration is typically 5–10 years, with longer durations considered for higher-risk cases. This approach aligns with guidelines from studies like TEXT/SOFT and organizations such as NCCN/ASCO.",NO
When can the Breast Cancer Index (BCI) test be offered for extended endocrine therapy decisions?,The BCI test may be offered to patients with 0-3 positive nodes who completed 5 years of endocrine therapy without recurrence.,"The Breast Cancer Index (BCI) test can be offered to **postmenopausal women with hormone receptor-positive (HR+), HER2-negative, early-stage breast cancer** who have completed **5 years of endocrine therapy without recurrence**, to assess the risk of late distant metastasis and predict benefit from extending endocrine therapy to 10 years. It aids in personalized decision-making for extended therapy.",NO
What are the benefits of adjuvant bisphosphonate therapy in postmenopausal breast cancer patients?,Adjuvant bisphosphonates improve overall survival modestly and reduce risks of bone recurrence and fracture rates.,"Adjuvant bisphosphonate therapy in postmenopausal breast cancer patients reduces bone recurrence, improves disease-free and overall survival (particularly in postmenopausal women, as shown in meta-analyses like EBCTCG), and prevents treatment-related bone loss (e.g., from aromatase inhibitors), lowering fracture risk. Benefits are attributed to inhibiting bone resorption and creating a hostile microenvironment for metastatic cells.",YES
"Which bisphosphonates are recommended for adjuvant therapy, and what are the doses?","Recommended options include oral clodronate (1,600 mg daily for 2-3 years), oral ibandronate (50 mg daily for 3 years), and zoledronic acid (4 mg every 6 months for 3 years).","**Recommended bisphosphonates for adjuvant therapy (e.g., in postmenopausal breast cancer to reduce recurrence/bone metastases):**  
- **Zoledronic acid**: 4 mg IV every 6 months.  
- **Clodronate**: 1600 mg orally daily.  

*Note: Use is typically on menopausal (natural or induced) patients, based on guidelines like ASCO/ESMO.*",NO
Should adjuvant denosumab be used to prevent recurrence in breast cancer?,Denosumab is not recommended as it does not consistently reduce recurrence rates.,"Adjuvant denosumab is not currently recommended to prevent breast cancer recurrence. While preclinical data suggested potential anti-tumor effects, the phase III D-CARE trial showed no significant improvement in disease-free survival in early breast cancer patients. Guidelines (e.g., ASCO, ESMO) do not endorse its use for recurrence prevention outside of clinical trials. Denosumab remains indicated for bone health (e.g., osteoporosis prevention in aromatase inhibitor-treated patients), not cancer outcomes.",YES
What is the recommendation for testing for ESR1 mutations in metastatic breast cancer?,Routine ESR1 mutation testing is not recommended,"The recommendation is to test for ESR1 mutations via liquid biopsy (circulating tumor DNA) in patients with ER-positive, HER2-negative metastatic breast cancer who have progressed on prior endocrine therapy (e.g., aromatase inhibitors). This helps guide treatment selection, such as using elacestrant or other targeted therapies. Tissue biopsy may be considered if liquid biopsy is negative. ASCO and ESMO endorse this approach to inform therapy decisions.",NO
What biomarker testing is advised for metastatic HER2-negative breast cancer with immune checkpoint inhibitor candidates?,Testing for PD-L1 expression in tumor and immune cells is recommended to determine eligibility for pembrolizumab plus chemotherapy.,"For metastatic HER2-negative breast cancer, particularly triple-negative subtype, **PD-L1 testing (using Combined Positive Score [CPS] ≥10)** is the primary biomarker advised to identify candidates for immune checkpoint inhibitors (e.g., pembrolizumab with chemotherapy). **Tumor mutational burden (TMB-H)** and **microsatellite instability (MSI-H)/mismatch repair deficiency (dMMR)** may be considered in select cases but are less routinely used. PD-L1 remains the key biomarker in this context.",YES
Should circulating tumor DNA (ctDNA) be routinely used to monitor therapy response in metastatic breast cancer?,Routine use of ctDNA for monitoring therapy response is not recommended due to insufficient data.,"Currently, ctDNA shows promise for monitoring therapy response in metastatic breast cancer due to its ability to detect tumor dynamics and resistance mutations non-invasively in real time. However, routine clinical use is not yet standard due to limitations in assay standardization, variable sensitivity/specificity, and insufficient evidence proving its impact on survival outcomes. It may complement existing methods (e.g., imaging) in select cases, but further validation in trials is needed before widespread adoption.",NO
Can adjuvant pembrolizumab be administered with radiation therapy?,Adjuvant pembrolizumab can be given concurrently with or after completion of radiation therapy.,"Yes, adjuvant pembrolizumab can be administered with radiation therapy. Clinical evidence supports their combined use in certain cancers (e.g., melanoma, head and neck cancers), often sequentially, to enhance immune response and reduce recurrence risk. However, timing and potential synergistic toxicity (e.g., increased inflammation or immune-related adverse events) must be carefully managed. Always follow specific clinical guidelines or trial protocols.",NO
How many years of abemaciclib should be used in combination with endocrine therapy in high-risk early-stage breast cancer?,"Two years of abemaciclib (150 mg twice daily) with endocrine therapy for ≥5 years may be offered to patients with high-risk hormone receptor-positive, HER2-negative early-stage breast cancer.","Abemaciclib should be used for **2 years** in combination with endocrine therapy for high-risk early-stage HR+/HER2- breast cancer, as supported by the MonarchE trial. Endocrine therapy typically continues for 5-10 years.",YES
What are the criteria for high-risk early breast cancer suitable for abemaciclib treatment?,"Criteria include ≥4 positive axillary lymph nodes or 1-3 positive nodes with tumor size ≥5 cm, histologic grade 3, or Ki-67 ≥20%.","High-risk early breast cancer suitable for abemaciclib treatment includes **HR-positive, HER2-negative** patients with:  
- **≥4 positive lymph nodes** or  
- **1-3 positive lymph nodes** plus **additional high-risk features** (tumor size ≥5 cm, grade 3, or Ki-67 ≥20%).  

Abemaciclib is used **adjuvantly** alongside endocrine therapy, typically for 2 years, following surgery and standard chemotherapy if indicated.",YES
Is the use of abemaciclib restricted to patients with a high Ki-67 score?,Abemaciclib is recommended for broader patient populations at high risk of recurrence regardless of Ki-67 status.,"No, the use of abemaciclib is not restricted to patients with a high Ki-67 score. It is approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy, regardless of Ki-67 status. Clinical trials and regulatory approvals do not specify Ki-67 as a criterion for its use.",YES
What is the role of olaparib in early-stage HER2-negative breast cancer with germline BRCA mutations?,Olaparib is recommended for one year after (neo)adjuvant chemotherapy and local treatment in high-risk early-stage HER2-negative breast cancer with BRCA mutations.,"Olaparib, a PARP inhibitor, is used as adjuvant therapy in early-stage HER2-negative breast cancer patients with germline BRCA1/2 mutations who are at high risk of recurrence (e.g., triple-negative or high-risk hormone receptor-positive disease). It targets BRCA-deficient cells via synthetic lethality, improving invasive disease-free and overall survival when administered after surgery and chemotherapy, typically for one year. This approval, based on the OlympiA trial, reduces recurrence risk in this specific population.",YES
What clinical criteria define high-risk patients eligible for olaparib?,"Eligibility includes triple-negative tumors >2 cm or node involvement, or hormone receptor-positive disease with ≥4 involved lymph nodes or a CPS-EG score ≥3.","High-risk patients eligible for olaparib are defined by:  
1. **Germline BRCA1/2 mutations** (key across indications).  
2. **Cancer type and context**:  
   - **Ovarian cancer**: Maintenance after platinum-based chemotherapy (BRCA-mutated or HRD-positive advanced cases).  
   - **Breast cancer**: HER2-negative, high-risk early-stage (e.g., lymph node involvement, residual post-neoadjuvant chemo).  
   - **Prostate/pancreatic cancer**: Metastatic disease with HRR gene alterations (e.g., BRCA mutations).  
3. **Prior treatment**: Response to platinum-based therapy (ovarian) or completion of adjuvant chemotherapy (breast).  

*Criteria vary by specific cancer type and regulatory approval.*",NO
What are the main findings from the OlympiA trial regarding olaparib?,The OlympiA trial demonstrated improved invasive and distant disease-free survival with olaparib compared to placebo.,"The OlympiA trial demonstrated that adjuvant olaparib significantly improved invasive disease-free survival (IDFS) and overall survival (OS) in patients with germline BRCA1/2-mutated, HER2-negative, high-risk early breast cancer after completing standard treatments. Olaparib reduced the risk of recurrence or death by 42% (IDFS) and showed a 32% reduction in mortality risk (OS) compared to placebo, with a manageable safety profile. These findings support olaparib as a standard adjuvant therapy for this specific population.",YES
"What is the recommendation for first-line treatment of triple-negative, PD-L1-positive metastatic breast cancer?",The addition of immune checkpoint inhibitors (atezolizumab or pembrolizumab) to chemotherapy is recommended.,"The first-line recommendation for triple-negative, PD-L1-positive metastatic breast cancer is **chemotherapy (e.g., paclitaxel, nab-paclitaxel, or platinum-based agents) combined with an immune checkpoint inhibitor** such as **pembrolizumab** (if CPS ≥10) or **atezolizumab** (if IC ≥1%). This approach is supported by trials like KEYNOTE-355 and IMpassion130, showing improved outcomes in PD-L1-positive patients.",YES
"What is the preferred treatment for triple-negative, PD-L1-negative metastatic breast cancer?",Single-agent chemotherapy is preferred,"The preferred treatment for triple-negative, PD-L1-negative metastatic breast cancer is **chemotherapy**, typically using agents such as taxanes (e.g., paclitaxel), anthracyclines (e.g., doxorubicin), or platinum-based regimens (e.g., carboplatin). Combination therapies (e.g., paclitaxel + carboplatin) or sequential single-agent regimens are common first-line options. For patients with BRCA mutations, PARP inhibitors (e.g., olaparib) may be considered. Sacituzumab govitecan (an antibody-drug conjugate) is an option in later lines. Clinical trials are encouraged due to the aggressive nature of this subtype.",NO
"What therapies are recommended for HR-positive HER2-negative metastatic breast cancer with BRCA mutations, who have progressed on endocine therapy?",Oral PARP inhibitors (olaparib or talazoparib) are recommended ,"For HR-positive, HER2-negative metastatic breast cancer with BRCA mutations progressing on endocrine therapy, recommended therapies include:  
1. **PARP inhibitors** (olaparib, talazoparib) — first-line due to BRCA mutation.  
2. **Platinum-based chemotherapy** (e.g., carboplatin) — effective in BRCA-associated tumors.  
3. **Sacituzumab govitecan** (antibody-drug conjugate) — if further progression occurs.  
These options prioritize targeting DNA repair deficiencies (PARP inhibitors/platinum) or leveraging tumor-specific antigen delivery (sacituzumab). Always consider clinical trial eligibility.",YES
"For patients with  HR-positive, HER2-negative who develop recurrence within one year of adjuvant AI therapy, what is the recommended in replacment of AI?",Fulvestrant or CDK4/6 inhibitors should be offered,"For patients with HR-positive, HER2-negative breast cancer recurring within one year of adjuvant AI therapy, the recommended treatment is **fulvestrant (an estrogen receptor antagonist) combined with a CDK4/6 inhibitor** (e.g., abemaciclib, palbociclib, or ribociclib). This approach is preferred due to demonstrated efficacy in endocrine-resistant disease. Chemotherapy may be considered for aggressive or symptomatic recurrences.",YES
"When is sentinel lymph node biopsy not required for patients with early-stage hormone receptor-positive, HER2-negative invasive breast cancer?",Sentinel lymph node biopsy is not required for clinically node-negative women aged ≥70 years who will receive hormonal therapy.,"Sentinel lymph node biopsy (SLNB) may be omitted in patients with early-stage hormone receptor-positive, HER2-negative invasive breast cancer when:  
- **Tumor size is very small (T1a/b, ≤1 cm)**.  
- **Older age or significant comorbidities** limit life expectancy or tolerance for additional treatments.  
- **Nodal status will not alter systemic therapy decisions** (e.g., endocrine therapy is planned regardless).  
- **Patient preferences** align with avoiding the procedure when clinical management remains unchanged.  

This approach is supported by guidelines (e.g., ASCO, NCCN) in select low-risk cases where axillary surgery does not impact adjuvant plans.",NO
How should axillary treatment be approached for patients undergoing mastectomy with 1-2 positive sentinel nodes?,"Postmastectomy radiation to the axilla is recommended, and axillary lymph node dissection can be safely omitted.","For patients undergoing mastectomy with 1-2 positive sentinel nodes, axillary lymph node dissection (ALND) is recommended if post-mastectomy radiation therapy (PMRT) is **not** planned. If PMRT is indicated (e.g., due to tumor size, high-risk features), ALND may be omitted, as PMRT typically includes axillary radiation. The decision should integrate tumor biology, patient preferences, and multidisciplinary evaluation.",NO
What are the recommendations for radiotherapy after neoadjuvant chemotherapy in node-positive early-stage breast cancer?,Locoregional nodal irradiation is recommended,"Radiotherapy is generally recommended after neoadjuvant chemotherapy for node-positive early-stage breast cancer, particularly if residual nodal disease (ypN+) is present. For patients who convert to node-negative (ypN0) after chemotherapy, guidelines still often advise radiotherapy, especially if initial clinical stage was high (e.g., cN1 with large tumors or cN2/cN3). Post-mastectomy radiotherapy (PMRT) is typically recommended for those with ≥4 positive nodes initially or residual disease. Regional nodal irradiation is also considered for 1-3 nodes with residual disease. Ongoing trials are evaluating potential de-escalation in ypN0 cases. Always consult current guidelines (e.g., NCCN, ASTRO) for patient-specific recommendations.",YES
"What is the recommended neoadjuvant therapy for HER2-positive, node-positive breast cancer?",Patients should receive neoadjuvant therapy with an anthracycline and taxane-based regimen in combination with trastuzumab and pertuzumab.,"The recommended neoadjuvant therapy for HER2-positive, node-positive breast cancer is a combination of **pertuzumab, trastuzumab, and chemotherapy** (typically docetaxel and carboplatin, known as the TCHP regimen). This dual HER2-targeted therapy with chemotherapy is the standard approach to shrink tumors before surgery.",NO
"How should neoadjuvant endocrine therapy be used in HR-positive, HER2-negative early-stage breast cancer?","For postmenopausal patients, neoadjuvant endocrine therapy with an aromatase inhibitor may be offered to increase surgical options.","Neoadjuvant endocrine therapy (NET) is recommended for **postmenopausal women** with **strongly HR-positive, HER2-negative early-stage breast cancer**, particularly when chemotherapy is unsuitable (e.g., due to comorbidities, low-risk features, or patient preference). **Aromatase inhibitors** (e.g., letrozole) are preferred over tamoxifen. Treatment typically lasts **4–8 months**, with regular monitoring (clinical exam, imaging) to assess response. If tumors shrink sufficiently, surgery follows; poor response may prompt switching to chemotherapy. NET helps downstage tumors and evaluate endocrine sensitivity but is less commonly used than chemotherapy in this setting.",YES
What is the recommendation for first-line therapy for esophageal SCC with PD-L1 TPS≥1%?,Administer nivolumab plus fluoropyrimidine- and platinum-based chemotherapy.,"The recommended first-line therapy for esophageal squamous cell carcinoma (SCC) with PD-L1 TPS ≥1% is **nivolumab combined with chemotherapy** (fluorouracil and cisplatin), based on improved survival demonstrated in the CheckMate 648 trial. This regimen is endorsed by guidelines such as NCCN and ESMO for PD-L1-positive cases.",YES
When is ramucirumab plus paclitaxel recommended?,For advanced gastroesophageal cancer patients progressing after first-line therapy.,Ramucirumab plus paclitaxel is recommended as a second-line treatment for advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients whose disease has progressed after first-line platinum and fluoropyrimidine-based chemotherapy.,YES
What is recommended for HER2-positive gastric cancer patients after progression on first-line therapy?,Trastuzumab deruxtecan is recommended.,"For HER2-positive gastric cancer patients progressing after first-line therapy (trastuzumab + chemotherapy), the recommended next-line treatment is **trastuzumab deruxtecan (T-DXd)**, an antibody-drug conjugate, if HER2 positivity is confirmed. This is supported by the DESTINY-Gastric01 trial showing improved outcomes. Other options include chemotherapy (e.g., ramucirumab + paclitaxel) or clinical trials. Retesting HER2 status post-progression is advised, as HER2 expression may change.",YES
Should adjuvant chemotherapy be recommended for stage II colon cancer patients with dMMR/MSI tumors?,Adjuvant fluoropyrimidine-only chemotherapy is not recommended.,"No, adjuvant chemotherapy is generally not recommended for stage II colon cancer patients with dMMR/MSI-H tumors. These tumors have a favorable prognosis and show limited or no benefit from conventional 5-FU-based chemotherapy, with some evidence suggesting potential harm. Current guidelines (e.g., NCCN, ASCO) advise against its use in this subgroup, favoring surveillance instead. Exceptions may involve high-risk features, but dMMR/MSI-H status typically outweighs such considerations.",YES
Should adjuvant chemotherapy be offered for low-risk stage II colon cancer patients?,ACT is not routinely recommended.,"Adjuvant chemotherapy is not routinely recommended for low-risk stage II colon cancer patients (no high-risk features like T4 tumors, obstruction, perforation, poor differentiation, or lymphovascular invasion). Current guidelines (e.g., ASCO, NCCN) reserve it for high-risk cases, as the modest survival benefit in low-risk patients does not outweigh treatment risks. Shared decision-making, considering patient preferences and tumor biomarkers (e.g., MSI status), is advised.",YES
What is the duration of oxaliplatin-based chemotherapy for high-risk stage II colon cancer?,"3 or 6 months, decided based on patient preference and potential for adverse events.","The duration of oxaliplatin-based chemotherapy for high-risk stage II colon cancer is typically **3 months for CAPOX regimen** (6 cycles) or **6 months for FOLFOX regimen** (12 cycles), depending on the specific protocol and clinical guidelines.",YES
What chemotherapy is recommended as radiosensitizer for stage I-III anal SCC?,Mitomycin-C with fluorouracil (FU) or capecitabine.,"The recommended chemotherapy as a radiosensitizer for stage I-III anal squamous cell carcinoma (SCC) is **5-fluorouracil (5-FU) combined with mitomycin C (MMC)**. This regimen is administered concurrently with radiation therapy, based on established efficacy in clinical trials.",YES
How should patients with BRAF V600E-mutant mCRC receive after prior chemotherapy?,Encorafenib plus cetuximab is recommended.,"Patients with BRAF V600E-mutant mCRC after prior chemotherapy should receive targeted therapy with **encorafenib (BRAF inhibitor) + cetuximab (EGFR inhibitor)**, based on improved survival outcomes in the BEACON trial. This combination is the standard of care for second-line or later treatment. Clinical trials or alternative regimens may be considered if unavailable.",YES
Should anti-EGFR be added as the first-line therapy for RAS mutatnt left-sided mCRC?,"No,  anti-EGFR is added for RAS wild type left-sided mCRC","No, anti-EGFR therapy (e.g., cetuximab, panitumumab) should not be added as first-line therapy for **RAS mutant left-sided metastatic colorectal cancer (mCRC)**. RAS mutations predict resistance to anti-EGFR agents, regardless of tumor sidedness. Current guidelines recommend avoiding anti-EGFR therapy in RAS-mutant mCRC, favoring anti-VEGF agents (e.g., bevacizumab) instead. Tumor location (left vs. right) primarily impacts outcomes in **RAS wild-type** tumors, not RAS-mutant cases.",NO
When is stereotactic body radiation therapy recommended for liver oligometastases in mCRC?,It may be recommended after systemic therapy if resection is not feasible.,"Stereotactic body radiation therapy (SBRT) is recommended for liver oligometastases in metastatic colorectal cancer (mCRC) when patients have **1-5 lesions** (oligometastatic disease), are **not candidates for surgery or ablation**, have **controlled primary disease**, and maintain **good performance status**. It is typically used for **local tumor control** after systemic therapy or as part of a multidisciplinary approach, particularly for lesions ≤5 cm and when prolonged survival is anticipated.",NO
How long is the healing period from dental procedure before radiation therapy for head and neck cancer patients to prevent osteoradionecrosis (ORN)?,Ensure at least a 2-week healing period when possible.,"The recommended healing period after dental procedures before starting radiation therapy for head and neck cancer patients is **14 to 21 days**. This allows adequate time for tissue healing (e.g., epithelialization of extraction sites) to reduce the risk of osteoradionecrosis (ORN). Timely dental intervention and coordination between dental and oncology teams are critical to minimize complications.",YES
What are the surgical recommendations for advanced-stage ORN in head and neck cancer patients?,"For advanced ORN, surgical debridement or resection with vascularized bone reconstruction is recommended to restore function and manage complications.","For advanced-stage osteoradionecrosis (ORN) in head and neck cancer patients, surgical intervention is typically required. Key recommendations include:  
1. **Radical resection** of necrotic bone to achieve clear margins.  
2. **Reconstruction** using vascularized free flaps (e.g., fibula, scapula) to restore function and structure.  
3. **Adjunctive therapies**: Antibiotics for infection control, pentoxifylline-tocopherol (PENTO) to aid healing, and hyperbaric oxygen in select cases.  
4. **Multidisciplinary collaboration** (surgeons, oncologists, dental specialists) for comprehensive care.  

Surgery remains the cornerstone for managing advanced ORN, prioritizing disease control and functional restoration.",YES
Should immunotherapy single agent be initiated in metastatic head and neck squamous cell carcinoma (HNSCC) with PD-L1 < 1?,"No, combination therapy is preferred for CPS <1.","No, single-agent immunotherapy is not recommended as first-line treatment for metastatic HNSCC with PD-L1 <1. The KEYNOTE-048 trial showed no significant survival benefit with pembrolizumab monotherapy in this subgroup. Instead, combination therapy (immunotherapy + chemotherapy) is preferred regardless of PD-L1 status. Guidelines recommend reserving single-agent immunotherapy for PD-L1 CPS ≥1.",YES
What are the guidelines for immunotherapy in platinum-refractory recurrent or metastatic HNSCC?,Pembrolizumab or nivolumab should be offered to patients regardless of PD-L1 CPS status.,"The guidelines for platinum-refractory recurrent or metastatic HNSCC recommend **anti-PD-1 inhibitors (nivolumab or pembrolizumab)** as second-line therapy, based on trials like CheckMate 141 and KEYNOTE-040 demonstrating survival benefits over chemotherapy. Key points:  
- **Nivolumab** or **pembrolizumab** are preferred regardless of PD-L1 status, though PD-L1 testing (e.g., CPS ≥1) may help predict response.  
- **NCCN guidelines** endorse these agents for patients with good performance status (ECOG 0-1).  
- No prior immunotherapy exposure is assumed.  
- Combination regimens (e.g., pembrolizumab + chemotherapy) are typically reserved for first-line treatment.  
- Monitor for immune-related adverse events.",YES
What is the recommendation for PD-L1 biomarker testing in recurrent/metastatic HNSCC?,"PD-L1 immunohistochemistry testing is recommended, and a CPS ≥1 is considered positive for PD-1 inhibitor therapy.","The recommendation for PD-L1 biomarker testing in recurrent/metastatic HNSCC is to perform PD-L1 Combined Positive Score (CPS) testing at diagnosis to guide first-line immunotherapy decisions. A CPS ≥1 is typically required for pembrolizumab monotherapy or combination therapy, while CPS ≥20 may indicate stronger benefit for pembrolizumab alone. Testing ensures eligibility for anti-PD-1/PD-L1 therapies, per guidelines like NCCN and evidence from trials such as KEYNOTE-048.",YES
Can radiation therapy be integrated with immunotherapy for recurrent HNSCC?,Radiation therapy may be safely administered concurrently with immunotherapy for palliative or local control in oligometastatic settings,"Yes, radiation therapy can be integrated with immunotherapy for recurrent head and neck squamous cell carcinoma (HNSCC). Emerging evidence suggests that radiation may enhance the immune response by releasing tumor antigens, potentially synergizing with checkpoint inhibitors (e.g., pembrolizumab, nivolumab) to improve outcomes. Clinical trials have shown promising results, including improved local control and survival, though optimal protocols (e.g., timing, dosing) and long-term safety are still under investigation. This combination is considered a viable strategy, often explored in trials or under multidisciplinary guidance.",NO
What are the PARP inhibitor recommendations for newly diagnosed advanced ovarian cancer responding to platinum-based chemotherapy?,"PARP inhibitors are recommended as maintenance therapy for BRCA-mutated or HRD-positive patients, with varying regimens based on genetic status.","For newly diagnosed advanced ovarian cancer patients responding to platinum-based chemotherapy, **PARP inhibitors** are recommended as maintenance therapy based on biomarker status:  
- **BRCA-mutated (germline/somatic):** Olaparib or niraparib.  
- **HRD-positive (including BRCA wild-type):** Olaparib combined with bevacizumab.  
- **HRD-negative/unknown:** Niraparib may be considered, though benefit is less pronounced.  

Recommendations align with NCCN guidelines and trials (SOLO-1, PRIMA, PAOLA-1). Biomarker testing (BRCA/HRD) is critical for tailored therapy.",YES
What is the effect of PARP inhibitors on patients' overall survival in recurrent ovarian cancer without BRCA-mutation or HRD-positivity?,Evidence suggests potential overall survival detriments in later-line treatments with PARP inhibitors,"In recurrent ovarian cancer patients without BRCA mutations or HRD-positivity, PARP inhibitors generally show limited or no significant improvement in overall survival (OS). While they may extend progression-free survival (PFS) in some cases, the absence of homologous recombination deficiency (HRD) reduces synthetic lethality, diminishing their efficacy. Clinical trials (e.g., NOVA, ARIEL3) often report OS benefits primarily in HRD-positive or BRCA-mutated subgroups, with minimal or non-significant OS gains in HRD-negative populations. Thus, their impact on OS in this specific patient group remains modest.",NO
What is the effect of PARP inhibitors on patients' progression-free survival in recurrent ovarian cancer without BRCA-mutation or HRD-positivity?,PARP inhibitors demonstrated progression-free survival benefits,"In recurrent ovarian cancer patients without BRCA mutations or HRD-positivity, PARP inhibitors provide a **modest improvement in progression-free survival (PFS)** compared to placebo, particularly when used as maintenance therapy after platinum-based chemotherapy. However, the benefit is **significantly smaller** than in patients with BRCA mutations or HRD-positive tumors. For example, trials like NOVA and ARIEL3 reported median PFS gains of ~3-6 months in HRD-negative subgroups, versus more robust improvements in biomarker-positive groups. Their use in this population is guided by clinical judgment and residual treatment response.",YES
What surgical approach is recommended for T3-T4 parotid cancers with high-grade malignancy?,"At least a superficial parotidectomy, with consideration of total or subtotal parotidectomy.","For T3-T4 high-grade parotid cancers, the recommended surgical approach is **total parotidectomy with en bloc resection of involved adjacent structures** (e.g., skin, muscle, bone) and **selective or therapeutic neck dissection** (due to high nodal metastasis risk). **Facial nerve sacrifice** is required if infiltrated, with potential grafting for functional restoration. Clear margins are prioritized, and adjuvant radiotherapy ± chemotherapy is typically added postoperatively.",NO
What is the recommended follow-up imaging schedule for high-grade salivary gland cancers post-treatment?,"Baseline imaging at 3 months, every 6-12 months for the first 2 years, and symptom-directed imaging from years 3-5. Yearly chest CT may be considered for high-grade cases.","For high-grade salivary gland cancers post-treatment, follow-up imaging is generally recommended **every 3-6 months for the first 2-3 years**, then **annually for up to 5 years**, guided by clinical assessment and institutional protocols. MRI or CT scans are commonly used, with PET-CT reserved for suspected recurrence. Always tailor the schedule to individual risk and multidisciplinary team recommendations.",NO
What chemotherapy regimen is recommended for stage III-IVA nasopharyngeal carcinoma (NPC) during induction?,"Platinum-based regimens such as GP (gemcitabine and cisplatin) or TPF (docetaxel, cisplatin, 5-fluorouracil) every 3 weeks for 2-3 cycles.","The recommended induction chemotherapy regimen for stage III-IVA nasopharyngeal carcinoma is **gemcitabine plus cisplatin (GP)**, based on phase III trial evidence showing improved survival. This is typically followed by concurrent cisplatin-based chemoradiation. Alternative regimens like TPF (docetaxel, cisplatin, 5-FU) may be used but are less favored due to higher toxicity.",YES
What radiotherapy technique is preferred for stage II-IVA nasopharyngeal carcinoma?,Intensity-modulated radiotherapy (IMRT) with daily image guidance is strongly recommended.,"The preferred radiotherapy technique for stage II-IVA nasopharyngeal carcinoma is **intensity-modulated radiation therapy (IMRT)**. It offers precise tumor targeting while minimizing radiation exposure to adjacent critical structures (e.g., spinal cord, parotid glands), improving outcomes and reducing side effects like xerostomia.",YES
What is the role of adjuvant chemotherapy for T3N0 nasopharyngeal carcinoma patients?,"Adjuvant chemotherapy may be offered, typically using a PF regimen.","Adjuvant chemotherapy is often recommended for T3N0 nasopharyngeal carcinoma (NPC) following concurrent chemoradiotherapy (CCRT) to reduce recurrence risk, particularly for distant metastases. While it is part of standard care for stage III disease (which includes T3N0), its benefit in this subgroup is debated. Recent studies suggest it may offer limited survival gains compared to CCRT alone, especially in patients with good treatment response or low-risk features (e.g., undetectable post-treatment EBV DNA). Decisions are individualized, weighing potential toxicity against perceived benefits.",NO
What is the schedule of radiation recommended for radiotherapy in nasopharyngeal carcinoma?,A dose of 70 Gy in 33-35 fractions (2.0-2.12 Gy per fraction) over 7 weeks is recommended.,"The standard radiotherapy schedule for nasopharyngeal carcinoma typically involves **66–70 Gy delivered in 1.8–2 Gy daily fractions over 6–7 weeks**, using intensity-modulated radiation therapy (IMRT). Concurrent chemotherapy (e.g., cisplatin) is often added for advanced stages (II–IV). Elective nodal regions receive 50–54 Gy. Adjustments may occur based on tumor stage and patient tolerance.",YES
What are the treatment options for MET exon 14 skipping mutation-positive NSCLC?,Capmatinib or tepotinib are recommended.,"The primary treatment for MET exon 14 skipping mutation-positive NSCLC is targeted therapy with MET tyrosine kinase inhibitors (TKIs) such as **capmatinib** or **tepotinib**, which are FDA-approved first-line options due to high response rates. If resistance occurs or TKIs are unavailable, options include **chemotherapy** (with or without immunotherapy) or off-label use of **crizotinib** (another MET inhibitor). Participation in **clinical trials** exploring newer MET inhibitors or combinations is also recommended. Molecular testing is essential to guide therapy selection.",YES
What is the guideline for first-line treatment in EGFR exon 20 insertion NSCLC?,Chemotherapy combined with amivantamab,"The first-line treatment guideline for EGFR exon 20 insertion NSCLC is **amivantamab (a bispecific EGFR/MET antibody) combined with platinum-based chemotherapy**, based on the phase 3 PAPILLON trial showing improved progression-free survival. If unavailable, platinum-doublet chemotherapy remains an option. Other targeted therapies (e.g., mobocertinib) are no longer recommended due to withdrawal or lack of confirmatory data.",YES
What is the recommended first-line treatment for stage IV NSCLC with EGFR exon 19 deletion mutation?,Osimertinib is recommended as the first-line treatment,"The recommended first-line treatment for stage IV NSCLC with EGFR exon 19 deletion mutation is **osimertinib**, a third-generation EGFR tyrosine kinase inhibitor (TKI), based on superior efficacy and CNS activity demonstrated in the FLAURA trial and endorsed by guidelines (NCCN, ESMO).",YES
How should patients with stage IV NSCLC and EGFR mutation progress after osimertinib treatment?,"Platinum-based chemotherapy, with or without amivantamab","For stage IV EGFR-mutant NSCLC progressing on osimertinib:  
1. **Assess progression pattern**: Local therapy (e.g., radiation) for oligoprogression; systemic therapy for widespread progression.  
2. **Molecular testing** (tissue/liquid biopsy) to identify resistance mechanisms (e.g., MET amplification, C797S mutation, HER2 alterations).  
3. **Targeted therapy** if actionable mutation (e.g., MET inhibitor + osimertinib for MET amplification).  
4. **Chemotherapy** (platinum-pemetrexed ± bevacizumab) if no targetable alteration.  
5. **Clinical trials** (e.g., fourth-generation TKIs, antibody-drug conjugates).  
6. **Supportive/palliative care** for symptom management.  
Prioritize biomarker-guided strategies and trial enrollment.",NO
What is the first line treatment for stage IV NSCLC with ROS1 fusion mutation?,"First-line treatment includes repotrectinib, entrectinib, or crizotinib.","The first-line treatment for stage IV NSCLC with a ROS1 fusion mutation is a ROS1 tyrosine kinase inhibitor, such as **entrectinib** or **crizotinib**. Entrectinib is often preferred due to its central nervous system activity, but both are standard options.",NO
What is the benefit of amivantamab plus lazertinib over osmiertinib alone in untreated EGFR mutation-positive stage IV NSCLC?,Amivantamab plus lazertinib showed a median PFS of 23.7 months compared to 16.6 months with osimertinib alone.,"The combination of amivantamab (an EGFR/MET bispecific antibody) and lazertinib (a third-generation EGFR TKI) demonstrated **significantly longer progression-free survival (PFS)** compared to osimertinib alone in untreated EGFR-mutant stage IV NSCLC, as shown in the MARIPOSA trial. This benefit likely stems from dual targeting of EGFR and MET pathways, which may delay resistance mechanisms (e.g., MET amplification) and enhance efficacy, including potential activity against brain metastases. However, the combination may have a higher toxicity burden.",NO
Should anti-PD-L1 be used for second-line therapy for EGFR mutation-positive NSCLC without targetable alterations?,Anti-PD-(L)1 agents are not recommended,"Anti-PD-L1 therapy is generally not recommended as second-line treatment for EGFR mutation-positive NSCLC without targetable alterations. EGFR-mutant tumors often respond poorly to immunotherapy due to low tumor mutational burden and PD-L1 expression. Clinical trials (e.g., KEYNOTE-789, CheckMate 722) showed limited efficacy for PD-1/PD-L1 inhibitors in this setting. Current guidelines prioritize chemotherapy (e.g., platinum-based regimens) or chemotherapy combined with anti-angiogenic agents (e.g., bevacizumab) after EGFR TKI failure. Immunotherapy may be considered in specific cases but lacks robust evidence for routine use.",YES
How should osimertinib be administered with chemotherapy for advanced EGFR-mutated NSCLC?,Osimertinib plus platinum-based chemotherapy with maintenance pemetrexed is recommended for certain patients.,"Osimertinib (80 mg orally once daily) is combined with platinum-based chemotherapy (cisplatin or carboplatin plus pemetrexed) every 3 weeks for 4 cycles, followed by maintenance pemetrexed, based on the FLAURA2 trial. This regimen improves progression-free survival in advanced EGFR-mutated NSCLC. Monitor for increased toxicity (e.g., myelosuppression, interstitial lung disease). Always follow current guidelines and adjust based on patient tolerance.",YES
What is the treatment recommendation for ROS1-positive NSCLC after progression on crizotinib?,Patients may be offered lorlatinib as a second-line treatment.,"The recommended treatment for ROS1-positive NSCLC after progression on crizotinib includes **next-generation ROS1 inhibitors** such as **lorlatinib** or **repotrectinib**, which target resistance mutations. **Clinical trials** for novel agents (e.g., taletrectinib) are also encouraged. If targeted options are unavailable, **platinum-based chemotherapy ± immunotherapy** may be used. Local therapies (e.g., radiation) can be considered for oligoprogressive disease. Molecular testing for resistance mutations (e.g., G2032R) may guide therapy selection.",NO
What is the efficacy of atezolizumab plus bevacizumab and chemotherapy in EGFR-mutated NSCLC?,"In the ATTLAS trial, this combination showed a median PFS of 8.48 months compared to 5.62 months with chemotherapy alone.","The combination of atezolizumab, bevacizumab, and chemotherapy (ABCP) in **EGFR-mutated NSCLC** showed promising efficacy in the **IMpower150 trial** subgroup analysis. For EGFR-positive patients who progressed on prior TKIs, ABCP demonstrated improved **progression-free survival (PFS)** and **overall survival (OS)** compared to bevacizumab + chemotherapy alone. However, this data is based on a small subgroup, and results should be interpreted cautiously. While not a first-line standard, this regimen may be considered for EGFR-mutant NSCLC after TKI failure, pending further validation.",NO
What are the recommendations for 1st line therapy in patients with MET exon 14 skipping mutations?,Capmatinib or tepotinib are recommended as first-line therapies.,"The recommended first-line therapies for patients with MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) are **capmatinib** and **tepotinib**, which are selective MET tyrosine kinase inhibitors (TKIs). These targeted therapies are preferred over chemotherapy or immunotherapy due to higher efficacy and response rates, as supported by clinical trials (e.g., GEOMETRY mono-1 for capmatinib, VISION for tepotinib). Testing for the mutation via molecular profiling is essential to guide treatment selection.",YES
What is the treatment for KRAS G12C-mutated NSCLC as 1st line therapy?,Chemotherapy,"The first-line treatment for KRAS G12C-mutated NSCLC typically involves **chemotherapy combined with immunotherapy** (e.g., pembrolizumab or atezolizumab) based on PD-L1 status. While targeted therapies like **sotorasib** and **adagrasib** are approved for KRAS G12C, they are currently used in the **second-line setting** after progression. Clinical trials are evaluating these inhibitors in first-line therapy, but standard-of-care remains chemo-immunotherapy until further evidence.",NO
What is the recommendation for RET rearrangement-positive NSCLC as 1st line therapy?,Selpercatinib or pralsetinib are recommended as first-line therapies.,"The recommended first-line therapy for RET rearrangement-positive NSCLC is targeted therapy with selective RET inhibitors, specifically **selpercatinib** or **pralsetinib**, as per guidelines (e.g., NCCN, ESMO). These agents are preferred over chemotherapy or immunotherapy due to higher efficacy and tolerability.",YES
How should clinicians manage EGFR T790M resistance alterations in advanced NSCLC?,Osimertinib is the recommended treatment for EGFR T790M resistance alterations.,"Upon progression on first-line EGFR TKI, clinicians should test for **T790M** using liquid biopsy (plasma ctDNA) and proceed to tissue biopsy if negative. If **T790M-positive**, treat with **osimertinib** (a third-generation EGFR TKI). If **T790M-negative**, transition to **platinum-based chemotherapy** ± bevacizumab. Re-biopsy at progression is critical to guide therapy.",NO
What is the first-line treatment for patients with stage IV NSCLC and PD-L1 TPS ≥50%?,Single-agent immunotherapy,"The first-line treatment for patients with stage IV NSCLC and PD-L1 TPS ≥50% (without actionable EGFR/ALK mutations) is **pembrolizumab (Keytruda) monotherapy**, an anti-PD-1 immunotherapy. This recommendation is based on the KEYNOTE-024 trial, which demonstrated superior survival outcomes compared to chemotherapy.",YES
Should single agent pembrolizumab be used for stage IV squamous NSCLC and PD-L1 expression 32%?,Pembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel) is recommended as first-line therapy.,"For stage IV squamous NSCLC with PD-L1 expression of 32% (1–49% range), **single-agent pembrolizumab is not preferred** as first-line therapy. Current guidelines (NCCN/ESMO) recommend **pembrolizumab combined with chemotherapy** for PD-L1 <50%, as this combination improves outcomes compared to monotherapy or chemotherapy alone. Single-agent pembrolizumab is reserved for PD-L1 ≥50% unless chemotherapy is contraindicated.",NO
What is the recommended therapy for stage IV NSCLC with PD-L1 TPS of 0?,Pembrolizumab plus carboplatin and pemetrexed,"For stage IV NSCLC with PD-L1 TPS 0% and no actionable driver mutations, first-line therapy typically involves **platinum-based chemotherapy combined with immunotherapy** (e.g., pembrolizumab + chemotherapy), regardless of PD-L1 status. If actionable mutations (e.g., EGFR, ALK) are present, targeted therapies are prioritized. Always confirm molecular testing and assess patient eligibility for immunotherapy.",YES
What are the options for patients with stage IV NSCLC with squamous histology and PD-L1 TPS ≥50%?,"Single-agent pembrolizumab, cemiplimab, or atezolizumab, or combination with chemotherapy, may be offered.","For patients with stage IV squamous NSCLC and PD-L1 TPS ≥50%, first-line options include:  
1. **Pembrolizumab monotherapy** (preferred based on survival benefit in KEYNOTE-024).  
2. **Pembrolizumab + chemotherapy** (platinum-based + gemcitabine/taxane) for rapid response or high tumor burden.  
3. **Nivolumab + ipilimumab** (dual immunotherapy, approved regardless of histology).  
Chemotherapy alone is reserved for those ineligible for immunotherapy. Treatment choice depends on patient factors and disease characteristics.",NO
What is the recommended adjuvant therapy for completely resected stage I-IIIA NSCLC with EGFR mutations?,Adjuvant osimertinib is recommended,"The recommended adjuvant therapy for completely resected stage IB-IIIA NSCLC with EGFR mutations is **osimertinib**, a third-generation EGFR tyrosine kinase inhibitor (TKI), based on the ADAURA trial, which demonstrated significant improvement in disease-free survival. Current guidelines (NCCN, ESMO) endorse osimertinib for 3 years, typically after adjuvant chemotherapy in higher-risk stages (II-IIIA), though it may be used alone in select cases.",YES
How should stage II-IIIA NSCLC patients with PD-L1 expression ≥1% be managed after surgery?,Adjuvant atezolizumab is recommended after cisplatin-based chemotherapy for patients with PD-L1 ≥1%.,"For stage II-IIIA NSCLC patients with PD-L1 ≥1% post-surgery, current guidelines recommend **adjuvant platinum-based chemotherapy followed by one year of adjuvant atezolizumab** (based on IMpower010 trial data), provided there are no contraindications. This approach improves disease-free survival in PD-L1-positive patients. EGFR/ALK testing is still advised to guide potential targeted therapy if mutations are present.",YES
What is the adjuvant therapy for resected stage IIB-IIIA NSCLC without EGFR mutations or high PD-L1?,Cisplatin-based chemotherapy is recommended as the adjuvant therapy.,"The adjuvant therapy for resected stage IIB-IIIA NSCLC without EGFR mutations or high PD-L1 is **platinum-based chemotherapy** (e.g., cisplatin with vinorebine, gemcitabine, or pemetrexed) followed by **pembrolizumab**, based on the KEYNOTE-091 trial. Pembrolizumab is now recommended post-chemotherapy regardless of PD-L1 status, per FDA approval and NCCN guidelines.",NO
Should osimertinib be recommended for stage IB NSCLC with tumors ≥4 cm with EGFR mutation?,Adjuvant osimertinib may be considered,"Yes, osimertinib is recommended for stage IB NSCLC (tumors ≥4 cm) with EGFR mutations based on the ADAURA trial, which showed significant disease-free survival benefit in adjuvant settings. Current guidelines support its use for resected stage IB-IIIA EGFR-mutant NSCLC, including high-risk stage IB (≥4 cm). However, long-term overall survival data remain pending, and decisions should consider patient-specific factors and multidisciplinary discussion.",NO
What is the recommended neoadjuvant therapy for resectable stage III NSCLC with N2 disease?,Neoadjuvant chemotherapy or concurrent chemoradiation,"The recommended neoadjuvant therapy for resectable stage III NSCLC with N2 disease is **platinum-based chemotherapy combined with nivolumab (an anti-PD-1 immunotherapy)**, based on the CheckMate 816 trial, which demonstrated improved outcomes over chemotherapy alone. This approach is supported by current guidelines (e.g., NCCN).",NO
What is the management for stage III NSCLC that is medically inoperable?,Concurrent chemoradiation is recommended as the definitive therapy,"The primary management for medically inoperable stage III NSCLC is **concurrent chemoradiotherapy** (platinum-based chemotherapy + radiation), followed by **durvalumab consolidation immunotherapy** (if no progression), based on the PACIFIC trial. For patients unfit for concurrent therapy, sequential chemotherapy followed by radiation may be used. Treatment is tailored to performance status and comorbidities.",YES
What is the evidence-based radiation dose for stage III NSCLC treated with chemoradiation?,A dose of 60 Gy in conventional fractionation is recommended for concurrent chemoradiation.,"The evidence-based standard radiation dose for stage III NSCLC treated with concurrent chemoradiation is **60 Gy in 30 fractions (2 Gy daily)** over 6 weeks, based on the RTOG 0617 trial. This trial demonstrated that higher doses (e.g., 74 Gy) worsened survival and increased toxicity. This regimen remains the guideline-recommended standard.",YES
What is the length of consolidation immunotherapy for patients with stage III NSCLC finished chemoradiation?,Consolidation durvalumab for up to 12 months is recommended,"The standard consolidation immunotherapy for stage III NSCLC after chemoradiation is **durvalumab**, administered **every 2 weeks for up to 12 months**, based on the PACIFIC trial protocol. This duration applies unless disease progression or intolerable toxicity occurs.",YES
"For patients with resected stage III NSCLC and EGFR mutation, should adjuvant chemotherapy still be offered?","Yes, platinum-based chemotherapy should be offered before osimertinib","Yes, adjuvant chemotherapy is still recommended for patients with resected stage III NSCLC and EGFR mutations, followed by EGFR-TKI therapy (e.g., osimertinib). While EGFR-TKIs like osimertinib significantly improve outcomes in the adjuvant setting (as shown in the ADAURA trial), current guidelines and trial protocols support combining chemotherapy with targeted therapy for optimal survival benefits. Chemotherapy remains a standard of care unless contraindicated.",YES
What is the maximum course of adjuvant pembrolizumab for resected stage IIB or IIC melanoma?,Adjuvant pembrolizumab is given as 200 mg every 3 weeks for a maximum of 15 courses.,"The maximum course of adjuvant pembrolizumab for resected stage IIB or IIC melanoma is **17 doses** (200 mg every 3 weeks), totaling approximately **1 year**, based on the KEYNOTE-716 trial protocol.",NO
What is the recommended therapy for resectable stage IIIB-IV cutaneous melanoma?,"Neoadjuvant pembrolizumab is recommended, followed by resection and adjuvant pembrolizumab.","The recommended therapy for resectable stage IIIB-IV cutaneous melanoma is **adjuvant immunotherapy with **anti-PD-1 agents (pembrolizumab or nivolumab)**. For **BRAF V600 mutation-positive patients**, adjuvant **BRAF/MEK inhibitors (dabrafenib + trametinib)** are also an option. These treatments aim to reduce recurrence risk post-surgery. Choice depends on mutation status, patient tolerance, and clinical context.",NO
What therapy should be avoided in BRAF-mutant unresectable melanoma after progression on anti-PD-1?,Ipilimumab-containing regimens should be avoided after progression on other therapies.,"After progression on anti-PD-1 therapy in BRAF-mutant unresectable melanoma, **BRAF inhibitor monotherapy** (e.g., vemurafenib or dabrafenib alone) should be avoided due to inferior efficacy and increased toxicity compared to combination BRAF/MEK inhibitors (e.g., dabrafenib + trametinib). Combination targeted therapy or alternative immunotherapies (e.g., anti-CTLA-4) are preferred options.",NO
What are the therapy options for metastatic uveal melanoma for HLA-A*02:01-positive patients?,Tebentafusp is recommended for HLA-A*02:01-positive patients with metastatic uveal melanoma.,"For HLA-A*02:01-positive patients with metastatic uveal melanoma, the primary FDA-approved therapy is **tebentafusp**, a bispecific T-cell engager targeting gp100. Additional options include immune checkpoint inhibitors (e.g., ipilimumab, pembrolizumab) with limited efficacy, and participation in clinical trials exploring novel immunotherapies or targeted therapies. Liver-directed therapies (e.g., embolization) may be considered for hepatic metastases.",YES
What radiation dose is suggested for brain metastases less than 2 cm in size?,Single-fraction SRS with 2000-2400 cGy is recommended.,"For brain metastases <2 cm, the suggested radiation dose is **20–24 Gy in a single fraction** using stereotactic radiosurgery (SRS), per standard protocols. Adjustments may occur based on tumor location or patient-specific factors.",YES
When is tumor size cutoff that surgery is preferred over SRS for brain metastases?,Surgery is conditionally recommended for brain metastases over 4 cm.,"The typical tumor size for preferring surgery over stereotactic radiosurgery (SRS) in brain metastases is **≥3 cm in diameter**. Larger tumors may respond less effectively to SRS due to reduced radiation efficacy and higher risk of complications like mass effect. However, decisions also depend on factors such as tumor location, patient symptoms, overall health, and number of metastases. Guidelines (e.g., NCCN) often cite 3-4 cm as a threshold, with surgery prioritized for symptomatic or accessible lesions. Always consider multidisciplinary evaluation for individualized care.",NO
"For asymptomatic brain metastases from EGFR-mutant NSCLC, should local therapy be offered?",Local therapy delayed until intracranial progression after osimertinib,"For asymptomatic brain metastases in EGFR-mutant NSCLC, current evidence supports initiating EGFR-TKIs (e.g., osimertinib) as first-line therapy due to their efficacy in controlling CNS disease. Local therapy (e.g., stereotactic radiosurgery) is not routinely recommended upfront but may be considered for select cases (e.g., larger lesions, oligometastatic disease) or upon progression. Shared decision-making is key, balancing potential benefits of early local intervention against risks like neurotoxicity. Guidelines generally favor deferring local therapy unless symptoms arise or systemic therapy fails.",NO
What is the number of brain mets that SRS be chosen over WBRT for unresected brain metastases?,SRS alone is recommended for 1-4 unresected brain metastases.,"SRS is generally preferred over WBRT for patients with 1 to 4 unresected brain metastases, though some guidelines extend this to up to 10 in select cases (e.g., small lesion size, controlled systemic disease). The decision depends on tumor volume, patient performance status, and institutional protocols.",NO
Should radiation therapy be offered to patients with KPS ≤ 50 and brain metastases?,Radiation therapy is not recommended for patients with KPS ≤ 50.,"Radiation therapy is generally not recommended for patients with brain metastases and a KPS ≤50 due to limited survival benefit and potential harms. Studies like the QUARTZ trial show that whole-brain radiation does not significantly improve survival or quality of life compared to supportive care alone. Exceptions may include select cases where short-course radiation could rapidly alleviate symptoms without significant toxicity. Prioritizing palliative care and symptom management is typically advised, with treatment decisions guided by individual prognosis and patient/family goals.",YES
"What is the alternative treatment for oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 2, due to toxicity concerns?",Temozolimide ,"The primary alternative to PCV chemotherapy for grade 2 IDH-mutant, 1p/19q-codeleted oligodendroglioma, due to toxicity concerns, is **temozolomide (TMZ)**. TMZ is better tolerated, with fewer side effects, and has shown efficacy in this subtype. Watchful waiting (active monitoring with MRI) may also be considered for asymptomatic, stable tumors. Dose-adjusted PCV or clinical trials exploring targeted therapies are additional options. Always tailor treatment to individual patient factors.",YES
"What alternative therapy is available for glioblastoma, IDH-wildtype, with poor prognosis?",Hypofractionated RT with TMZ or supportive care are reasonable options.,"Alternative therapies for glioblastoma, IDH-wildtype, with poor prognosis include:  
1. **Clinical trials**: Investigating targeted therapies (e.g., EGFR inhibitors), immunotherapies (checkpoint inhibitors, CAR-T), or oncolytic viruses.  
2. **Tumor-Treating Fields (TTFields)**: Noninvasive electric field therapy (e.g., Optune®) combined with chemotherapy.  
3. **Personalized approaches**: Biomarker-guided treatments (e.g., VEGF inhibitors like bevacizumab for recurrent cases).  
4. **Experimental options**: Gene therapy or combination therapies.  

**Note**: These therapies are not curative and require evaluation by a neuro-oncology team. Clinical trials remain the primary avenue for accessing emerging treatments.",NO
